Koo Chail, Richter Claus-Peter, Tan Xiaodong
Department of Otolaryngology-Head and Neck Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Hugh Knowles Center for Clinical and Basic Science in Hearing and Its Disorders, Northwestern University, Evanston, IL 60208, USA.
Pharmaceuticals (Basel). 2024 Jul 28;17(8):998. doi: 10.3390/ph17080998.
Hearing loss is a health crisis that affects more than 60 million Americans. Currently, sodium thiosulfate is the only drug approved by the Food and Drug Administration (FDA) to counter hearing loss. Sirtuins were proposed as therapeutic targets in the search for new compounds or drugs to prevent or cure age-, noise-, or drug-induced hearing loss. Sirtuins are proteins involved in metabolic regulation with the potential to ameliorate sensorineural hearing loss. The mammalian sirtuin family includes seven members, SIRT1-7. This paper is a literature review on the sirtuins and their protective roles in sensorineural hearing loss. Literature search on the NCBI PubMed database and NUsearch included the keywords 'sirtuin' and 'hearing'. Studies on sirtuins without relevance to hearing and studies on hearing without relevance to sirtuins were excluded. Only primary research articles with data on sirtuin expression and physiologic auditory tests were considered. The literature review identified 183 records on sirtuins and hearing. After removing duplicates, eighty-one records remained. After screening for eligibility criteria, there were forty-eight primary research articles with statistically significant data relevant to sirtuins and hearing. Overall, SIRT1 ( = 29) was the most studied sirtuin paralog. Over the last two decades, research on sirtuins and hearing has largely focused on age-, noise-, and drug-induced hearing loss. Past and current studies highlight the role of sirtuins as a mediator of redox homeostasis. However, more studies need to be conducted on the involvement of SIRT2 and SIRT4-7 in hearing protection.
听力损失是一场影响着超过6000万美国人的健康危机。目前，硫代硫酸钠是美国食品药品监督管理局（FDA）批准的唯一一种对抗听力损失的药物。在寻找预防或治疗年龄、噪音或药物引起的听力损失的新化合物或药物的过程中，沉默调节蛋白被提出作为治疗靶点。沉默调节蛋白是参与代谢调节的蛋白质，具有改善感音神经性听力损失的潜力。哺乳动物沉默调节蛋白家族包括七个成员，即SIRT1 - 7。本文是一篇关于沉默调节蛋白及其在感音神经性听力损失中的保护作用的文献综述。在NCBI PubMed数据库和NUsearch上进行的文献检索，关键词包括“沉默调节蛋白”和“听力”。与听力无关的沉默调节蛋白研究以及与沉默调节蛋白无关的听力研究均被排除。仅考虑具有沉默调节蛋白表达数据和生理听觉测试数据的原始研究文章。文献综述确定了183条关于沉默调节蛋白和听力的记录。去除重复记录后，还剩下81条记录。在筛选纳入标准后，有48篇原始研究文章具有与沉默调节蛋白和听力相关的具有统计学意义的数据。总体而言，SIRT1（= 29）是研究最多的沉默调节蛋白旁系同源物。在过去的二十年里，关于沉默调节蛋白和听力的研究主要集中在年龄、噪音和药物引起的听力损失上。过去和当前的研究强调了沉默调节蛋白作为氧化还原稳态介质的作用。然而，关于SIRT2以及SIRT4 - 7在听力保护中的作用，还需要进行更多的研究。
